Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Supported: GLP-1 drugs linked to lower kidney failure… | NewsLink (opens in a new tab)

news.tessapp.ai · 2026-10-19

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 5 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All five claims match what the study reports.

  • 5 supported
Open claim evidence
3
Source paper

Source layer

The 6 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5SupportedMayo Clinic researchers found that GLP-1 receptor agonists were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.View evidenceHide evidence

Why this verdict

The abstract-profile supports the headline’s central scientific claim: in adults with bipolar disorder and CKD stage ≤3, GLP-1 RA initiation was associated with lower observed risk of kidney replacement therapy, with the primary comparison versus DPP-4 inhibitors and a corroborating secondary comparison versus RAAS inhibitors. The claim is framed associationally rather than causally. The profile does not independently verify the Mayo Clinic attribution, but the main finding is supported.

1

Study evidence

GLP-1 RA use was associated with lower observed risk of kidney replacement therapy compared with DPP-4 inhibitor use.aHR 0.56 (95% CI 0.50–0.64)

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

GLP-1 RA initiators had lower observed risk of kidney replacement therapy compared with RAAS inhibitor initiators (aHR 0.66); after propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher for GLP-1 RA users (94.68% vs. 89.77%; P < .001).aHR 0.66

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users”
Claim 2 of 5SupportedThe study, published in the Journal of Clinical Psychiatry, suggests that a popular class of medications may offer an added benefit by helping protect kidney health in a high-risk group.View evidenceHide evidence

Why this verdict

The story’s wording is hedged—“suggests” and “may offer”—and aligns with the abstract-profile’s finding of lower observed KRT risk in a high-risk BD+CKD population. Because the story elsewhere notes the observational design and need for prospective studies, this speculative interpretation does not overstate causality. The journal name and “popular class” characterization are not established by the supplied profile, but the substantive claim is supported.

1

Study evidence

GLP-1 RA use was associated with lower observed risk of kidney replacement therapy compared with DPP-4 inhibitor use.aHR 0.56 (95% CI 0.50–0.64)

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

GLP-1 RA initiators had lower observed risk of kidney replacement therapy compared with RAAS inhibitor initiators (aHR 0.66); after propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher for GLP-1 RA users (94.68% vs. 89.77%; P < .001).aHR 0.66

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users”
Claim 3 of 5SupportedResearchers analyzed de-identified electronic health record data from TriNetX and compared adults with bipolar disorder and mild-to-moderate chronic kidney disease who had newly started a GLP-1 medication with patients taking DPP-4 inhibitors or RAAS inhibitors, using statistical matching and up to five years of follow-up.View evidenceHide evidence

As statedup to five years

Why this verdict

The profile supports the described design: TriNetX real-world EHR data, adults with bipolar disorder and CKD stage ≤3, new-user active-comparator cohorts, GLP-1 RA initiators compared with DPP-4 inhibitor initiators primarily and RAAS inhibitor initiators secondarily, propensity score matching/statistical adjustment, and Cox/time-to-event follow-up over 5 years. The supplied profile does not explicitly state “de-identified,” but the core methodological description is supported at abstract depth.

1

Study evidence

GLP-1 RA use was associated with lower observed risk of kidney replacement therapy compared with DPP-4 inhibitor use.aHR 0.56 (95% CI 0.50–0.64)

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

GLP-1 RA initiators had lower observed risk of kidney replacement therapy compared with RAAS inhibitor initiators (aHR 0.66); after propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher for GLP-1 RA users (94.68% vs. 89.77%; P < .001).aHR 0.66

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users”
Claim 4 of 5SupportedAcross both comparisons, GLP-1 use was associated with a lower risk of dialysis or kidney transplantation, and the pattern was generally consistent across sex, race, obesity status and use of psychiatric medications including lithium.View evidenceHide evidence

Why this verdict

The profile reports lower observed KRT risk for GLP-1 RA users in both the DPP-4 primary comparison and the RAAS secondary comparison. It also reports that apparent benefits were consistent across sex, race, obesity status, and psychotropic medication subgroups including lithium. The story appropriately describes subgroup consistency generally and does not invent subgroup-specific estimates.

1

Study evidence

GLP-1 RA use was associated with lower observed risk of kidney replacement therapy compared with DPP-4 inhibitor use.aHR 0.56 (95% CI 0.50–0.64)

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

GLP-1 RA initiators had lower observed risk of kidney replacement therapy compared with RAAS inhibitor initiators (aHR 0.66); after propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher for GLP-1 RA users (94.68% vs. 89.77%; P < .001).aHR 0.66

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users”
Claim 5 of 5SupportedBecause the study was observational, it cannot establish that GLP-1 medications caused the lower risk, and the researchers said prospective studies are needed to determine whether GLP-1 medications directly slow kidney disease progression.View evidenceHide evidence

Why this verdict

The profile explicitly characterizes the work as observational/exploratory and states that prospective studies are needed to assess causality. The story’s caveat that the study cannot establish that GLP-1 medications caused the lower risk is consistent with the paper profile.

1

Study evidence

GLP-1 RA use was associated with lower observed risk of kidney replacement therapy compared with DPP-4 inhibitor use.aHR 0.56 (95% CI 0.50–0.64)

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

GLP-1 RA initiators had lower observed risk of kidney replacement therapy compared with RAAS inhibitor initiators (aHR 0.66); after propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher for GLP-1 RA users (94.68% vs. 89.77%; P < .001).aHR 0.66

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Health care utilization was also a paper outcome, with reported lower adjusted HCU risk but no significant HCU-free survival difference after propensity matching in both comparator analyses.

    The story focuses on kidney failure/KRT outcomes and does not mention the HCU outcome or the important nuance that matched HCU-free survival comparisons were not significant.

    From new-user active-comparator cohort study (real-world EHR network); secondary active-comparator cohort study (TriNetX)

6 things the story did carry across
  • Primary study design: a TriNetX real-world, new-user active-comparator observational cohort study in adults with bipolar disorder and CKD stage ≤3, using propensity score matching and Cox/time-to-event modeling over 5 years.
  • Primary kidney finding: GLP-1 RA initiation was associated with lower observed kidney replacement therapy risk compared with DPP-4 inhibitor initiation; matched 5-year KRT-free survival was also higher.
  • Secondary comparator finding: a separate RAAS inhibitor comparison corroborated the lower observed KRT risk with GLP-1 RA use.
  • Subgroup/effect-modification analyses examined sex, race, ethnicity, obesity, and psychotropic medication use including lithium; the abstract reports generally consistent benefits but provides no subgroup-specific estimates or interaction statistics.
  • Causality limitation: the analyses are observational and exploratory; prospective studies are needed to evaluate whether GLP-1 RAs causally slow kidney disease progression or reduce KRT risk.
  • Generalizability is limited to adults with bipolar disorder and CKD stage ≤3 rather than all patients with CKD or all GLP-1 RA users.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataAssess whether GLP-1 receptor agonist (GLP-1 RA) initiation is associated with lower risk of kidney replacement therapy (KRT) and health care utilization (HCU) compared with an active comparator (DPP-4 inhibitor) in adults with bipolar disorder (BD) and chronic kidney disease (CKD stage ≤3) using real-world data with propensity score matching and time-to-event modeling.new-user active-comparator cohort study (real-world EHR network)Expand

In plain English

In a TriNetX real-world new-user active-comparator cohort of adults with bipolar disorder and stage ≤3 chronic kidney disease, initiation of GLP-1 receptor agonists (GLP-1 RA) was associated with lower observed risk of kidney replacement therapy (KRT) and lower observed health care utilization (HCU) compared with initiation of dipeptidyl peptidase-4 (DPP-4) inhibitors over 5 years; a secondary comparison versus renin-angiotensin-aldosterone system (RAAS) inhibitors corroborated the KRT finding.

Key findings

  • GLP-1 RA use was associated with lower observed risk of kidney replacement therapy compared with DPP-4 inhibitor use.aHR 0.56 (95% CI 0.50–0.64)
  • GLP-1 RA use was associated with lower observed health care utilization compared with DPP-4 inhibitor use.aHR 0.74 (95% CI 0.71–0.78)
“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
What this piece can’t prove
  • Observational EHR-based study (TriNetX); abstract notes findings are exploratory and that prospective studies are needed to assess causality.
  • Study population restricted to adults with bipolar disorder and CKD stage ≤3, which may limit generalizability beyond this group.
  • Abstract does not report details on covariates used in propensity score models or on outcome adjudication; potential for residual confounding and misclassification remains.
2secondary dataCorroborate/triangulate the primary association by repeating the comparative effectiveness analysis using a different active comparator cohort (RAAS inhibitor initiators) versus GLP-1 RA initiators.secondary active-comparator cohort study (TriNetX)Expand

In plain English

Secondary, real-world new-user active-comparator cohort analysis (TriNetX) comparing GLP-1 RA initiators versus RAAS inhibitor initiators among adults with bipolar disorder and stage ≤3 CKD. After propensity score matching (n=2,539 per group) and Cox regression over 5 years, GLP-1 RA use was associated with lower observed risk of kidney replacement therapy (KRT) and healthcare utilization (HCU) in unadjusted estimates; the KRT association remained in matched survival comparisons while HCU did not differ significantly after matching. Authors describe these as exploratory findings that warrant prospective study.

Key findings

  • GLP-1 RA initiators had lower observed risk of kidney replacement therapy compared with RAAS inhibitor initiators (aHR 0.66); after propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher for GLP-1 RA users (94.68% vs. 89.77%; P < .001).aHR 0.66
  • GLP-1 RA initiators had lower observed risk of healthcare utilization compared with RAAS inhibitor initiators (aHR 0.62), but after propensity score matching HCU-free survival did not differ significantly between groups (P = .15).aHR 0.62
“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users”
What this piece can’t prove
  • Abstract presents observational, exploratory analyses; authors state prospective studies are needed to assess causality.
  • Results are based on TriNetX EHR data and propensity score matching; potential for residual confounding, misclassification, and selection biases inherent to secondary data analyses.

1 further detail could not be confirmed from the summary.

3secondary dataExplore effect modification/heterogeneity of the GLP-1 RA associations across subgroups (sex, race, ethnicity, obesity, and psychotropic medication use including lithium).Subgroup/interaction analyses within propensity-score matched observational cohortExpand

In plain English

Within the TriNetX propensity-score matched cohorts of adults with bipolar disorder and chronic kidney disease initiating GLP-1 RA versus active comparators, subgroup/effect-modification analyses reported that the observed associations (GLP-1 RA–associated benefits) were consistent across examined subgroups defined by sex, race, ethnicity, obesity, and psychotropic medication use (including lithium).

Key findings

  • Subgroup analyses reported consistency of the GLP-1 RA–associated benefits across subgroups defined by sex, race, ethnicity, obesity, and psychotropic medication use (including lithium).
“Subgroup analyses examined effect modification by sex, race, ethnicity, obesity, and psychotropic medication use.”
What this piece can’t prove
  • Unclear whether subgroup analyses were prespecified and how multiple comparisons were handled.
  • Abstract does not report subgroup sample sizes or power to detect heterogeneity.
  • As these are analyses within an observational cohort, results may be subject to residual confounding and should be considered exploratory.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 12 candidate papers

Candidate

SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.

Journal of Affective Disorders · 2026 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
CandidateOpen access

GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.

Biology Methods & Protocols · 2026 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)

And 6 more candidates considered.